cdk7 (Bethyl)
Structured Review

Cdk7, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 17 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk7/product/Bethyl
Average 93 stars, based on 17 article reviews
Images
1) Product Images from "CDK7–CDK11 axis in spliceosome regulation and pre-mRNA splicing"
Article Title: CDK7–CDK11 axis in spliceosome regulation and pre-mRNA splicing
Journal: Nucleic Acids Research
doi: 10.1093/nar/gkaf1343
Figure Legend Snippet: CDK7 transiently binds CDK11. ( A ) Schematic representation of proteomic BioID experiment for identification of proteins proximal to CDK11. The N-terminus of CDK11 fused to biotin ligase (BirA) biotinylates nearby proteins in cells. The biotinylated proteins are purified and identified by mass spectrometry. ( B ) Volcano plot of proteins identified in CDK11 BioID. Splicing factors are marked in orange, components of the CDK11 complex in blue, CDK7 in cyan and other proteins in green. ( C ) Immunoblot analysis of immunoprecipitations of endogenous CDK11 after 4 h treatment with 50 nM SY-351 in HCT116 cells. Detected proteins are indicated on the right. IgG = antibody control.
Techniques Used: Purification, Mass Spectrometry, Western Blot, Control
Figure Legend Snippet: CDK11 is phosphorylated on canonical activating Thr595 in cells. ( A ) Amino acid sequence of T-loop of CDK11B. Activating Thr595 is in red. Peptide sequences used for the production of three (Ab1, Ab2, and Ab3) phospho-specific Thr595 antibodies are indicated by black bars. ( B ) Multiple protein sequence alignment of T-loop of CDKs. Activating Thr residues are highlighted in red, Ser corresponding to Ser164 in CDK7 is in orange. xDFG and APE motifs are indicated. ( C ) Immunoblot analysis of CDK11 in HCT116 cells upon treatment with control or CDK11 siRNAs for 40 h. Bands corresponding to CDK11 110 and P-CDK11 220 (monitored by Ab3) are marked on the right with arrows. “Long” and “short” corresponds to long and short exposure of the film. Asterisk denotes nonspecific bands. ( D ) Immunoblot analysis of CDK11 in HCT116 cells upon treatment with 50 nM SY-351 or control DMSO for 4 h. See Fig. for the legend. ( E ) Immunofluorescence microscopy of HCT116 cells using DAPI stain and the P-CDK11 220 (Ab2) and SF3B1 antibodies upon 100 nM treatment with SY-351 or control DMSO for 4 h; scale bar = 10 µm. ( F ) Quantification of P-CDK11 intensity (monitored by Ab2) in Fig. . Box plots represent median and IQR, whiskers extend to the furthest value inside 1.5 × IQR, asterisk: P < 0.05.
Techniques Used: Sequencing, Western Blot, Control, Immunofluorescence, Microscopy, Staining
Figure Legend Snippet: CDK7 is required for the formation of P-CDK11 220 and active spliceosomes. ( A ) Immunoblot analyses of indicated proteins in HCT116 cells treated with control DMSO or 50 nM SY-351 for 2 h and separated into cytoplasmic (cyto), nucleoplasm (nucl), and chromatin (chrom) fractions. Bands corresponding to CDK11 110 and P-CDK11 220 (monitored by Ab3) are marked on the right with arrows. CCNL1 is marked on the right with an arrow. “Long” and “short” corresponds to long and short exposure of the film. Asterisk denotes a nonspecific band. ( B ) Immunoblot analyses of indicated proteins in nucleoplasm and chromatin fractions (from Fig. ) separated by ultracentrifugation in 10%–40% glycerol gradient. Bands corresponding to CDK11 110 and P-CDK11 220 (monitored by Ab3) are marked on the right with arrows. Asterisks denote nonspecific bands. ( C ) Metagene analyses of P-CDK11 ChIP-Seq (using Ab2) on 8090 genes in cells treated with either control DMSO or 50 nM SY-351 for 2 h. Each transcript was divided into two parts with fixed length [transcription start site (TSS) −3 kb to +1.5 kb and transcription termination site (TTS) −1.5 kb to +20 kb] and a central part with variable length corresponding to the rest of gene body (shown in %). Each part was binned into a fixed number of bins (90/180/215), average coverage normalized to sequencing depth was calculated for each bin for each transcript in each sample and then averaged first across genes and second across samples. The color track at the bottom indicates the significance of paired Wilcoxon tests comparing the normalized transcript coverages for each bin between DMSO and SY-351 treatment. P ‐values are adjusted for multiple testing with the Bonferroni method within each subfigure; color code: red = adjusted P ‐value ≤ 10 −15 , orange = adjusted P ‐value ≤ 10 −10 , yellow = adjusted P ‐value ≤ 10 −3 . ( D ) IGV genome browser view of P-CDK11 220 ChIP-Seq on EZR gene in HCT116 cells treated with either control DMSO or 50 nM SY-351 for 2 h. SF3B1 and P-SF3B1 ChIP-seq on EZR gene in cells treated with control DMSO are shown below. noAb = control without antibody, R1, R2 = replicate 1, 2. T211 and T235 Ab = antibodies against P-Thr211 and P-Thr235 in SF3B1, respectively. Y -axis scale is denoted in square brackets.
Techniques Used: Western Blot, Control, ChIP-sequencing, Sequencing
Figure Legend Snippet: Onset of splicing deficiency after CDK7 inhibition correlates with P-CDK11 220 dephosphorylation. ( A ) Immunoblot analyses of proteins after treatment of HCT116 cells with control DMSO or 50 nM SY-351 for the indicated times. Bands corresponding to CDK11 110 and P-CDK11 220 are marked on the right with arrows. ( B ) DNA gel-visualised RT-PCR analyses of splicing of ARRDC4, CCNL1 , and RIOK1 transcripts after treatment of HCT116 cells with 100 nM SY-351 for the indicated times. Schema of unspliced and spliced transcripts, including order of the tested exons in each transcript, are depicted on the right. DNA represents control RT-PCR product from genomic DNA. ( C ) Graph shows ratio of unspliced to spliced transcripts of six genes measured by RT-qPCR in HCT116 cells treated with 50 nM SY-351 for indicated times. mRNA levels were normalised to PPIA mRNA and expression in control DMSO condition was set as 1. Error bars = SD, n = 3.
Techniques Used: Inhibition, De-Phosphorylation Assay, Western Blot, Control, Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Expressing
Figure Legend Snippet: Working Model. ( A ) CDK7 activity in normal cell. CDK7, as part of the TFIIH complex, phosphorylates the CTD of RNAPII to regulate promoter escape and normal transcription. CDK7, probably as part of the CAK complex, is also required for the onset of P-CDK11 220 , which is needed for the phosphorylation of SF3B1 (P-SF3B1) and activation of the spliceosome and normal splicing. ( B ) Consequences of short (<2 h) CDK7 inhibition with SY-351. Short inhibition blocks promoter escape, which results in a strong decrease in transcription, with some RNAPII slowly transcribing into the gene body. ( C ) Consequences of long (>2 h) CDK7 inhibition with SY-351. After a longer inhibition, the transcription is rescued by other transcriptional CDKs that phosphorylate the CTD of RNAPII . This results in faster elongation and synthesis of nascent RNA. The RNA is not spliced, because ongoing CDK7 inhibition blocks the formation of P-CDK11 220 and subsequent SF3B1 phosphorylation, which results in an inactive spliceosome and nonfunctional splicing.
Techniques Used: Activity Assay, Phospho-proteomics, Activation Assay, Inhibition

